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Original Article
Treatment patterns of patients diagnosed
with major headache disorders:
A retrospective claims analysis
David Kudrow1, Sagar Munjal2, Leah Bensimon2,
Tasneem Lokhandwala3 , Binglin Yue3,
Anna D’Souza Coutinho3, and Stephen D Silberstein4
Abstract
Objective: To describe patient characteristics, treatment patterns, and health care costs among patients diagnosed with
major headache disorders overall and by type (tension-type headache [TTH], migraine, cluster headache [CH], or >1
primary headache type), and secondarily to evaluate drug treatment patterns among triptan initiators with a major
headache diagnosis.
Methods: Using US claims data from January 2012 through December 2017, we identified adults with evidence of a major
headache disorder: TTH, migraine, or CH; the first diagnosis date was deemed the index date. To evaluate triptan use
specifically, patients who initiated triptans were identified; the first triptan claim date was deemed the index date. Patient
characteristics, treatment patterns (concomitant treatments, adherence, number of fills), and annual health care costs data
were obtained.
Results: Of the 418,779 patients diagnosed with major headache disorders, the following 4 cohorts were created: TTH
(8%), migraine (87%), CH (1%), and >1 primary headache type (4%). The majority used analgesic (54–73%) and psy-
chotropic (57–81%) drugs, primarily opioids (36–53%). Headache-related costs accounted for one-fifth of all-cause costs.
Of the 229,946 patients who initiated triptans, the following 7 study cohorts were analyzed: sumatriptan (68%), rizatriptan
(21%), eletriptan (5%), zolmitriptan (3%), naratriptan (2%), frovatriptan (1%), and almotriptan (<1%). The major con-
comitant analgesic medication classes were opioids (41%) and nonsteroidal anti-inflammatory drugs (34%).
Conclusion: The primary headache disorder treatment paradigm is complex, with significant variability. Predominant
concomitant use of opioids and switching to opioids is of concern, necessitating solutions to minimize opioid use.
Switching to non-oral/fast-acting or targeted preventive therapies should be considered.
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Introduction
Approximately half of the world’s adult population has
experienced a headache at least once within the last year;1
more than 90% of patients who present to their primary
care provider with symptoms are diagnosed with a primary
headache disorder.2 The global active prevalence of
tension-type headache (TTH) is approximately 40% and
migraine is 10%; cluster headache (CH) is rare, with a
population prevalence of 0.1%; and together these account
for the majority of primary headache disorder diagnoses.2
Despite being recognized as a public health concern, there
are few studies quantifying the prevalence and burden of all
headache disorders; existing studies have focused on indi-
vidual headache types. Understanding the treatment pat-
terns and burden of the major headache types may assist
in evidence-based treatment decisions as treatment para-
digms tend to overlap across the different subtypes.
Headache disorders are estimated to cost US$31 billion
in the United States each year.3 As per a real-world assess-
ment of the economic burden of migraine, compared with
matched non-migraine patients, migraine patients were
more likely to have work loss and longer periods of work
loss, leading to significantly higher indirect costs.4 While
limited literature is available on the burden of TTH, indi-
rect costs of non-migraine headaches (of which TTH is the
major contributor) are also higher than that of migraine
headaches.5 Additionally, studies6–8 have demonstrated
considerable absenteeism as a result of TTH, as high as
three times more than in migraine. It is reported that CH
patients have high health care costs associated with inpa-
tient admissions and high indirect costs associated with
absenteeism and short-term disability.9 In a study that uti-
lized US claims data, the CH-related total direct costs were
US$3132 per patient per year. Additionally, CH-related
inpatient hospitalizations (US$1604) and pharmacy
(US$809) together (US$2413) contributed over 75% of the
CH-related direct health care cost.9
Previous research investigating pharmacologic treat-
ment patterns from 2008 to 2009 in insured patients with
migraine using a large claims database reported that 66%
received acute migraine-specific medication, while only
20% received US Food and Drug Administration (FDA)-
approved prophylactic migraine therapy.10 The relatively
low percentage of patients who received an FDA-approved
migraine preventive therapy may be attributed to off-label
preventive medication use for migraine. A secondary anal-
ysis of the pooled National Ambulatory Medical Care Sur-
vey from 2011 and 2012 demonstrated that of 12.9 million
outpatient visits for pediatric patients with a migraine diag-
nosis, 66.7% received at least 1 migraine drug and, of these,
off-label medications were prescribed 1.5 times more than
FDA-approved medications for children (60.34% vs.
39.65%).11 A systematic review of adults with episodic
migraine reported that among off-label drug classes,
angiotensin-inhibiting drugs (angiotensin-converting
enzyme inhibitors and angiotensin receptor blockers) were
more effective in reducing monthly migraine by 50%
compared with antidepressants, off-label antiepileptics, and
ergot alkaloids.12 In a retrospective analysis using claims
data from 2009 to 2014, the most commonly prescribed
drug classes for CH patients included opiate agonists
(41%), corticosteroids (34%), 5HT-1 agonists (32%), anti-
depressants (31%), nonsteroidal anti-inflammatory drugs
(NSAIDs) (29%), anticonvulsants (28%), calcium antago-
nists (27%), and benzodiazepines (22%).13 The literature
on treatment patterns among patients diagnosed with TTH
is scarce.
The objective of this study was to primarily describe
patient characteristics, pharmacologic treatment patterns,
annual all-cause and headache-related health care resource
utilization (HCRU), and costs among patients diagnosed
with major headache disorders overall and by type (TTH,
migraine, CH, or >1 primary headache type) and seconda-
rily to evaluate drug treatment patterns among triptan
initiators with a major headache diagnosis.
Methods
Data source
Data on patient characteristics, treatment patterns, HCRU,
and costs were obtained from the integrated health care
claims data from the IBM MarketScan Commercial Claims
and Encounters (commercial) and Medicare Supplemental
(Medicare) databases. The commercial database consists of
employer and health plan-sourced data containing medical
and drug claims for over 50 million individuals annually.
Enrollees are employees, Medicare-eligible retirees, and
their dependents insured by employer-sponsored benefit
plans. The Medicare Supplemental database contains the
inpatient and outpatient medical and prescription claims of
Medicare-eligible persons with supplemental insurance
plans offered by their former employers. Since this study
used deidentified patient records for analysis, it was exempt
from institutional review board approval.
Study design and population
This study employed a retrospective cohort design using
data from January 1, 2012, to December 31, 2017. For the
analysis of major headache disorders overall, the target
population was adults with evidence of a major headache
disorder: TTH (International Classification of Diseases,
Ninth Revision, Clinical Modification [ICD-9-CM]:
307.81, 339.1x; Tenth Revision [ICD-10-CM]: G44.2x),
migraine (ICD-9-CM: 346.x; ICD-10-CM: G43.0x,
G43.1x, G43.4x-G43.9x, G43.Bx, G43.Cx), or CH (ICD-
9-CM: 339.00, 339.01, 339.02; ICD-10-CM: G44.00x,
G44.01x, G44.02x) any time during the study period.
Patients were required to have 2 nondiagnostic medical
claims with a diagnosis for the same type of major
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headache disorder occurring30 and365 days apart dur-
ing the study period. Patients who satisfied the criteria for
>1 major headache disorder were classified into the >1
headache type cohort. The date of the first observed non-
diagnostic medical claim containing a primary or second-
ary diagnosis of a major headache disorder during the
identification period (January 1, 2013-December 31,
2016), was defined as the index date.
For the evaluation of triptan initiators specifically, the
target population consisted of adults who initiated triptans
during the identification period (January 1, 2013–Decem-
ber 31, 2016) with evidence of a major headache disorder
diagnosis. The date of the first observed triptan claim dur-
ing the identification period was defined as the index date.
Patients were required to be continuously enrolled for the
12 months pre- and post-index date.
Patient demographic and clinical characteristics
Patient demographics such as age, gender, geographic
region, health plan type, urban/rural residence, and index
year were measured as of the index date. Clinical charac-
teristics were measured for both study populations over the
12-month pre-index period and included the Charlson
Comorbidity Index (CCI) score, which was computed for
each patient based on the presence of ICD-9/10-CM diag-
nosis codes and represents overall comorbidity. In addition,
specific comorbid conditions (i.e. angina, anxiety disor-
ders, arthritis, osteoarthritis, rheumatoid arthritis, bipolar
spectrum disorders, additional headache types, and so
forth) and additional symptoms of interest (i.e. nausea,
photophobia, phonophobia, and vomiting) were assessed
using ICD-9/10-CM diagnosis codes.
Outcomes
HCRU and costs were computed by setting of care over the
12 months post-index; annual all-cause and headache-
related (claims with a primary or secondary diagnosis of
TTH, migraine, or CH) HCRU were presented. All costs
were defined as the actual reimbursements paid by health
plans plus any patient cost sharing in the form of deducti-
bles, copayments, and coinsurance. All cost estimates were
adjusted to the most recent year (2017) US$ by the medical
component of the Consumer Price Index. Components of
the total costs (medical and prescription) were computed.
The use of analgesic and psychotropic medications over
the 12 months post-index was reported; the number of pre-
scription claims was also computed. The proportions of
patients on recognized treatments for headache, stratified
by acute/abortive and preventive/prophylactic treatment,
were captured over the 12 months post-index. For prophy-
lactic medications, proportion of days covered (PDC) over-
all was reported (days with multiple drugs/drug classes [as
applicable] on hand were counted once). For acute medica-
tions, the average number of claims by medication class
was reported (a 90-day supply prescription counted as 3
claims). Recognized acute and prophylactic treatments
were identified from a combination of published litera-
ture,14,15 treatment guidelines,16–19 and clinical input.
Among triptan initiators, triptan use patterns were com-
puted over a variable follow-up period: up to the end of
enrollment or end of study period, whichever came first.
The proportion of patients with only one triptan fill was
reported. Patients who continued to refill the index triptan
were considered persistent to their index triptan. In this
way, persistency was defined as consecutive refills of the
initially prescribed triptan, regardless of duration between
refills. To better capture patients with a low frequency of
attacks, patients were censored: if the end of the follow-up
period occurred after 90 days following the last day of
possession of the index triptan, that patient was classified
as nonpersistent.20 For nonpersistent patients, the number
of index triptan fills before discontinuation was reported.
Proportions of nonpersistent patients with evidence of a
non-index triptan, opioid, or NSAID claim after the last
index triptan claim were reported. Patients were required
to have no evidence of use of the concerned class of med-
ication over the 12 months prior to switch date to be clas-
sified as switchers.
High triptan use was defined as dispensing of triptan
pills, sprays, or injections at a level that suggested the
patient was treating more than 24 headaches during any
90-day rolling period. For this calculation, it was assumed
that a quantity of two pills or injections (regardless of
strength or specific triptan), two sprays of nasal sumatrip-
tan, one subcutaneous injection of zolmitriptan, or one
spray of nasal zolmitriptan was used for each headache.10
Statistical analysis
The study was descriptive in nature. All demographic and
clinical variables measured during the baseline period and
outcomes measured during the follow-up period were ana-
lyzed descriptively through the tabular display of means,
standard deviations (SDs), medians, and percentiles for
continuous measures and frequency distributions for cate-
gorical variables. All data management and analyses were
conducted using SAS version 9.4.
Results
For the analysis of all major headache disorders, a total of
418,779 patients were included; the following 4 cohorts
were created: TTH (8%; n ¼ 34,147), migraine (87%;
n ¼ 363,976), CH (1%; n ¼ 4326), and >1 primary head-
ache type (4%; n¼ 16,330) (Table 1). The mean age ranged
from 44.1 years (migraine cohort) to 48.2 years (CH
cohort). The majority of CH patients were male (62.2%),
whereas in the TTH cohort, those with migraine, and >1
headache type patients were predominantly female (76.0–
83.7%). Approximately 40% of the patients across all study
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Table 1. Baseline demographics and clinical characteristics of patients diagnosed with major headache disorders.
Characteristics
TTH Migraine CH >1 Headache type
n ¼ 34,147 n ¼ 363,976 n ¼ 4326 n ¼ 16,330
Measured as of index date
Age in years, mean (SD) 44.9 (14.1) 44.1 (13.6) 48.2 (13.4) 44.3 (13.1)
Age group in years, n (%)
18–24 3188 (9.3) 37,608 (10.3) 230 (5.3) 1424 (8.7)
25–34 5212 (15.3) 53,545 (14.7) 480 (11.1) 2368 (14.5)
35–44 8317 (24.4) 91,117 (25.0) 960 (22.2) 4355 (26.7)
45–54 8685 (25.4) 95,953 (26.4) 1184 (27.4) 4480 (27.4)
55–64 6578 (19.3) 67,465 (18.5) 1119 (25.9) 2934 (18.0)
65þ 2167 (6.4) 18,288 (5.0) 353 (8.2) 769 (4.7)
Females, n (%) 25,961 (76.0) 304,598 (83.7) 1637 (37.8) 13,227 (81.0)
Geographic region, n (%)
Northeast 4756 (13.9) 63,019 (17.3) 798 (18.5) 2723 (16.7)
North Central 8401 (24.6) 78,735 (21.6) 996 (23.0) 3582 (21.9)
South 13,680 (40.1) 157,722 (43.3) 1804 (41.7) 6828 (41.8)
West 7118 (20.9) 60,434 (16.6) 691 (16.0) 3070 (18.8)
Unknown 192 (0.6) 4066 (1.1) 37 (0.9) 127 (0.8)
Plan type, n (%)
Unknown 321 (0.9) 3913 (1.1) 49 (1.1) 150 (0.9)
FFS 1539 (4.5) 15,785 (4.3) 254 (5.9) 637 (3.9)
EPO/PPO 20,951 (61.4) 224,244 (61.6 2670 (61.7) 10,313 (63.2)
HMO 3143 (9.2) 43,455 (11.9) 453 (10.5) 1789 (11.0)
POS with/without capitation 2254 (6.6) 28,238 (7.8) 326 (7.5) 1326 (8.1)
CDHP/HDHP 5939 (17.4) 48,341 (13.3) 574 (13.3) 2115 (13.0)
Measured over the baseline period
CCI, mean (SD) 0.4 (1.0) 0.4 (0.9) 0.5 (1.1) 0.5 (1.0)
Other primary/secondary headachesa, n (%)
Vascular headache (not elsewhere classified) 9847 (28.8) 97,381 (26.8) 1399 (32.3) 7310 (44.8)
Specific comorbidities,a n (%)
Allergies/hay fever 5228 (15.3) 50,244 (13.8) 527 (12.2) 3088 (18.9)
Anxiety disorders 6049 (17.7) 58,726 (16.1) 596 (13.8) 3772 (23.1)
Arthritis 3109 (9.1) 32,823 (9.0) 403 (9.3) 1787 (10.9)
Osteoarthritis 2811 (8.2) 28,777 (7.9) 375 (8.7) 1588 (9.7)
Chronic pain 1256 (3.7) 14,393 (4.0) 204 (4.7) 1043 (6.4)
Circulation problems 11,017 (32.3) 115,291 (31.7) 1616 (37.4) 5901 (36.1)
Cardiac disease 4434 (13.0) 47,319 (13.0) 685 (15.8) 2535 (15.5)
Hypertension 7875 (23.1) 77,449 (21.3) 1214 (28.1) 4025 (24.6)
Depression 2686 (7.9) 27,417 (7.5) 243 (5.6) 1768 (10.8)
Diabetes 2343 (6.9) 20,602 (5.7) 324 (7.5) 1059 (6.5)
Fibromyalgia 3924 (11.5) 30,412 (8.4) 266 (6.1) 2359 (14.4)
GERD 4550 (13.3) 45,093 (12.4) 542 (12.5) 2680 (16.4)
Hypercholesterolemia 6026 (17.6) 62,852 (17.3) 1021 (23.6) 3326 (20.4)
Menopause symptoms 2074 (6.1) 20,495 (5.6) 122 (2.8) 1100 (6.7)
Migraine with aura 755 (2.2) 19,856 (5.5) 118 (2.7) 2285 (14.0)
Obesity 3038 (8.9) 28,600 (7.9) 334 (7.7) 1558 (9.5)
Sinusitis 8097 (23.7) 86,284 (23.7) 872 (20.2) 4980 (30.5)
Vitamin D deficiency 2138 (6.3) 19,334 (5.3) 229 (5.3) 1183 (7.2)
Specific symptoms, n (%)
Nausea 2510 (7.4) 33,503 (9.2) 281 (6.5) 2155 (13.2%)
Vomiting 1423 (4.2) 22,026 (6.1) 174 (4.0) 1308 (8.0)
Disturbance of skin sensation 3427 (10.0) 40,070 (11.0) 387 (8.9) 2154 (13.2)
Insomnia 2479 (7.3) 22,977 (6.3) 274 (6.3) 1650 (10.1)
CCI: Charlson Comorbidity Index; CDHP: consumer-driven health plan; CH: cluster headache; EPO: exclusive provider organization; FFS: fee-for-
service; GERD: gastroesophageal reflux disease; HDHP: high-deductible health plan; HMO: health maintenance organization; POS: point of service; PPO:
preferred provider organization; SD: standard deviation; TTH: tension-type headache.
aSpecific primary/secondary headaches and comorbidities <5% have not been reported.
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cohorts were from the South (attribute of the data), and the
majority resided in urban areas (83.3–85.3%). The mean
CCI ranged from 0.4 (TTH and migraine) to 0.5 (CH and
>1 headache types). The most prevalent comorbidities
across all four cohorts were sinusitis (20–31%), hyperten-
sion (21–28%), and anxiety disorders (14–23%). The high
proportion of patients with comorbid sinusitis may indicate
misdiagnosis of headache disorders. The majority (98.8%)
of the patients in the >1 headache type study cohort had a
diagnosis of migraine and TTH.
For the evaluation of triptan initiators, of the 1,114,406
patients with at least 1 claim for a triptan, 229,946 (20.6%)
were included in the final sample; patients were mainly
excluded due to noncontinuous enrollment in the health
plan during the 12-month pre- and post-index periods. Of
the final sample, the majority were sumatriptan initiators
(68.0%), followed by rizatriptan (20.7%), eletriptan
(5.1%), zolmitriptan (3.3%), naratriptan (1.7%), frovatrip-
tan (0.9%), and almotriptan (0.4%) (Table 2). The mean
(SD) age of the triptan initiators was 40.0 (12.9) years,
ranging from 39.5 (13.0) years (sumatriptan) to 45.1
(12.7) years (almotriptan). The majority of patients were
35–54 years old, female (81.4%), and from the South
(44.4%) and resided in urban areas (85.8%). The mean
(SD) CCI was 0.3 (0.8) for the overall study population
and remained similar across study cohorts. Approximately,
three-fourths of the study population had a CCI score of 0.
The most prevalent comorbidities overall were sinusitis
(23.9%), hypertension (16.8%), circulation problems
(25.3%), and anxiety disorders (16.7%). The proportions
of patients with specific comorbidities and symptoms did
not differ significantly across study groups.
HCRU and costs
Among patients diagnosed with major headache disorders,
one-tenth (7.7–9.8%) of the patients were hospitalized over
the 12-month post-index period, and one-third had emer-
gency department (ED) visits (26.3–36.3%). Almost all
patients had a physician office visit over the post-index
period (97.9–99.7%), with mean (SD) number of visits over
the 12-month period ranging from 8.4 (7.1) (CH) to 12.3
(9.1) (>1 headache type). Physician office visits were further
evaluated by specialty type, and 20.7–54.2% of patients had
evidence of a neurologist visit (mean [SD] number of visits
¼ 0.6 [1.8] to 2.1 [3.1]), 58.1–65.8% of patients visited a
primary care provider (mean [SD] number of visits ¼ 2.7
[4.9] to 3.8 [6.0]), and 15.3–38.1% of patients visited an
obstetrician/gynecologist (mean [SD] number of visits ¼
0.3 [1.2] to 0.9 [1.9]) over the 1 year. Patients diagnosed
with >1 headache type incurred the highest mean (SD) total
annual all-cause costs (US$17,853 [US$32,073]), followed
by migraine (US$15,320 [US$31,802]), CH (US$15,037
[US$40,018]), and TTH (US$12,825 [US$27,829]). The
medical costs were primarily driven by outpatient/ancillary
visits (other than physician office visits). Headache-related
costs accounted for approximately one-fifth of all-cause
costs.
Treatment patterns
Among patients diagnosed with major headache disorders,
the majority had evidence of analgesic (53.7–72.9%) (pro-
portions vary across primary headache disorder diagnoses
[Table 3]) and psychotropic (56.6–80.5%) drug use. The
predominant analgesic medication classes used were
opioids (35.8–53.0%) and NSAIDs (30.5–40.9%). The
mean (SD) number of analgesic prescription claims over
1 year ranged from 3.1 (6.1) for the TTH cohort to 5.9 (8.9)
for patients diagnosed with >1 headache type. The mean
(SD) number of opioid prescription claims ranged from 1.7
(4.4) for the TTH cohort to 3.5 (6.7) for patients diagnosed
with >1 headache type. The predominant psychotropic
medication classes were antidepressants (33.1–58.5%) and
mood stabilizers (21.6–50.9%). Patients diagnosed with
>1 headache type had the highest mean (SD) number of
psychotropic prescription claims over the year (15.3
[17.6]), followed by migraine (11.9 [16.0]), CH (8.5
[13.8]), and TTH (8.4 [13.5]) cohorts. Antidepressant and
mood stabilizer use was highest among patients diagnosed
with >1 headache type (mean [SD] number of prescription
claims ¼ 6.8 [9.4] and 5.1 [8.5], respectively), followed by
the migraine cohort (mean [SD] number of prescription
claims ¼ 5.3 [8.4] and 3.9 [7.5], respectively). Adherence
to recognized prophylactic treatments was low; the mean
(SD) PDC ranged from 0.2 (0.3) for the TTH cohort, to
0.4 (0.4) for patients diagnosed with >1 headache type.
Triptans were the second predominant acute headache-
related treatment used (10.4–50.3%) after opioids
(36.6–54.1%) among all study cohorts, except patients
diagnosed with TTH. The TTH cohort had evidence of
predominant opioid use (36.6%) followed by NSAID use
(21.7%). The migraine cohort had the highest proportion of
patients on triptans (50.3%), with a mean (SD) number of
prescriptions ¼ 2.5 (4.6) over the 12-month post-index
period. Patients diagnosed with >1 headache type had the
highest proportion with opioid use (54.1%), followed by
migraine (46.6%), CH (44.3%), and TTH (36.6%) cohorts.
Higher proportions of patients used strong opioids
(29.5–45.7%) across all study cohorts than weak opioids
(14.3–23.3%). Oxygen therapy was predominant among
patients diagnosed with CH (17.9%) compared with the
other study cohorts (0.4–3.3%). Sumatriptan was the most
commonly used triptan followed by rizatriptan; a higher
proportion of triptan users among patients diagnosed with
CH used sumatriptan (81.1%) when specific triptan use was
compared across study cohorts. Non-oral sumatriptan use
was more common among patients diagnosed with CH
when compared across all study cohorts (Figure 1).
Among triptan initiators, the majority had evidence of
concomitant analgesic (58.4%) and psychotropic (64.8%)
drug use (Table 4). The predominant analgesic medication
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Measured as of index date
Age in years, mean (SD) 40.0 (12.9) 39.5 (13.0) 42.7 (12.8) 41.5 (12.6) 40.5 (12.6) 45.1 (12.7) 41.7 (12.1) 42.4 (11.8)
Age group in years, %
18–24 15.7 16.9 11.3 12.4 14.3 9.2 11.1 9.9
25–34 19.5 20.3 15.8 16.7 18.7 10.7 17.1 14.2
35–44 27.4 26.9 27.3 29.6 28.3 25.1 29.7 31.9
45–54 23.0 22.1 26.5 24.6 24.1 30.1 26.3 28.5
55–64 12.4 11.8 16.7 14.3 12.9 21.6 14.2 13.3
65þ 2.0 2.1 2.4 2.4 1.7 3.3 1.7 2.2
Females, % 81.4 80.0 82.6 88.0 84.1 87.4 85.0 89.3
Geographic region, %
Northeast 14.9 14.7 17.4 15.3 13.6 18.5 18.8 22.9
North Central 21.3 22.5 19.2 22.7 18.9 20.0 16.7 13.5
South 44.4 42.1 47.2 41.3 49.9 45.6 51.2 46.5
West 18.6 19.9 15.4 19.7 16.7 14.8 12.5 16.1
Unknown 0.8 0.8 0.8 1.1 0.9 1.1 0.9 1.0
Plan type, %
FFS 3.1 3.3 2.9 2.6 2.7 4.4 2.8 2.6
EPO/PPO 60.2 59.2 63.5 56.0 61.7 61.3 66.4 67.6
HMO 12.5 13.3 9.4 17.0 11.5 7.9 8.6 9.1
POS with/without
capitation
7.2 7.0 8.2 8.3 7.2 7.9 8.4 8.2
CDHP/HDHP 15.9 16.3 14.9 15.4 15.9 17.0 12.7 11.2
Unknown 1.0 1.0 1.1 0.8 1.0 1.6 1.2 1.3
Measured over the baseline
period
CCI, mean (SD) 0.3 (0.8) 0.3 (0.8) 0.3 (0.8) 0.4 (0.8) 0.4 (0.8) 0.4 (0.9) 0.3 (0.8) 0.4 (0.8)
Other primary/secondary headache,a %
Vascular headache (not
elsewhere classified)
26.9 26.7 27.9 35.8 26.2 20.7 29.4 29.1
Specific comorbiditiesa, %
Allergies/hay fever 13.8 13.2 15.4 15.5 14.6 14.5 16.3 15.1
Anxiety disorders 16.7 16.6 16.5 18.5 16.8 14.2 17.1 18.1
Arthritis 6.6 6.3 8.1 6.6 6.9 8.8 7.8 8.8
Osteoarthritis 5.7 5.5 6.9 5.7 6.0 8.5 6.7 7.3
Chronic pulmonary
disease
10.4 10.3 11.0 12.0 10.4 11.1 11.2 11.1
Circulation problems 25.3 24.6 28.4 28.8 26.1 30.7 28.4 27.7
Cardiac disease 9.4 9.1 10.7 11.6 9.8 12.7 10.6 10.9
Hypertension 16.8 16.5 18.0 18.1 17.1 19.9 18.2 18.2
Depression 7.7 7.7 7.9 9.5 7.6 9.1 8.0 8.0
Diabetes 4.7 4.7 4.3 4.0 4.8 7.1 4.8 4.9
Fibromyalgia 6.8 6.4 7.9 9.4 7.3 7.4 8.6 9.2
GERD 11.1 10.8 12.3 12.3 11.6 13.6 12.3 13.5
Hypercholesterolemia 12.7 12.3 15.0 12.7 12.9 19.2 14.4 14.6
Menopause symptoms 4.4 4.0 5.4 5.4 4.9 7.0 5.8 6.7
Migraine with aura 8.0 6.9 13.5 12.7 8.7 13.5 12.5 13.9
Obesity 8.4 8.5 8.0 9.0 8.4 7.9 7.7 8.5
Sinusitis 23.9 23.3 24.2 24.5 25.2 25.2 26.9 25.1
Vitamin D deficiency 5.2 5.0 6.0 6.0 5.5 8.0 5.8 6.8
Specific symptoms, %
Nausea 10.6 10.6 10.4 12.2 10.6 7.8 10.5 11.6
Vomiting 6.8 6.9 6.9 6.5 6.8 5.3 6.7 7.0
Disturbance of skin
sensation
9.9 9.6 10.3 12.6 10.1 11.2 10.7 11.4
Insomnia 6.4 6.1 7.5 7.8 6.6 6.8 7.5 7.6
(continued)
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classes used were opioids (40.6%) and NSAIDs (34.1%).
The mean (SD) number of analgesic prescription claims
over the 12-month post-index period was 3.0 (5.7). Higher
proportions of naratriptan initiators had evidence of con-
comitant analgesic drug use (including a higher mean num-
ber of analgesic prescription claims) compared with the
other triptan initiators, whereas the proportion of sumatrip-
tan initiators with concurrent analgesic, psychotropic, and
prophylactic drug use was the lowest among all triptan
initiators. The majority of the triptan initiators had evi-
dence of concomitant prophylactic headache-related treat-
ment (56.5%), and the mean (SD) PDC for prophylactic
treatments was 0.3 (0.3).
Index triptan use patterns were computed over a vari-
able follow-up period. The mean (SD) follow-up time for
the study population was 29.9 (13.2) months and rela-
tively similar across all study cohorts. Overall, 42.4%
of the study population had only one claim for a triptan
(including the index claim) over follow-up; the proportion
of patients with only one triptan fill was highest among
sumatriptan initiators (44.2%) and lowest among almo-
triptan initiators (29.9%). Overall, 84.0% of triptan initia-
tors were nonpersistent to index triptan therapy and had
on average 2.7 (+3.2) index triptan fills before disconti-
nuation. The proportion of patients nonpersistent to index
triptan therapy was similar across all triptan initiators. Of
the nonpersistent patients, 45.4% switched to NSAIDs,
opioids, or a non-index triptan and had on average 1.9
(+2.1) index triptan fills before switching. Of the switch-
ers, 64.9% switched to opioids, 62.1% switched to
NSAIDs, and 6.6% switched to a non-index triptan. These
results were similar across study cohorts. Additionally,
9.3% of triptan initiators had evidence of high triptan
use; the proportion of patients with high triptan use was
the highest among almotriptan initiators (13.5%) and low-
est among sumatriptan initiators (8.4%). Higher propor-
tions (27.2–36.4%) of patients who initiated non-oral
triptans had evidence of oral triptans over follow-up,
whereas among patients initiating oral triptans, only
2.8% and 1.7% had evidence of a subcutaneous and intra-
nasal triptan over follow-up. Differential discontinuation
of treatment by index route of administration may affect
this conclusion.
Discussion
This retrospective observational cohort study was con-
ducted using a linked medical and pharmacy claims data-
base to evaluate patient characteristics and treatment
patterns among patients diagnosed with major headache
disorders overall and by headache type, and treatment pat-
terns among triptan users diagnosed with TTH, migraine, or
CH. The study demonstrated that the majority of patients
diagnosed with major headache disorders had evidence of
analgesic and psychotropic drug use, primarily opioids,
NSAIDs, and antidepressants. Adherence to recognized
prophylactic treatments was low. Triptans were the predo-
minant acute headache treatment after opioids for all
cohorts except TTH patients. Patients diagnosed with CH
had evidence of triptan use and were more likely to use
non-oral triptans. Headache-related resource utilization
accounted for approximately 20% of total health care costs
incurred by these patients.
Opioids were the most predominant concomitant acute
headache-related treatment used, followed by NSAIDs.
Higher proportions of patients used strong opioids overall
than weak opioids; this was consistent across all study
cohorts. Among triptan initiators, switching to opioid or
NSAID therapy was prevalent. The use of oral triptans was
more favorable in comparison to non-oral triptan therapy
(>90% of the population had a migraine diagnosis).
Approximately one-tenth of patients had evidence of high
triptan use.
Consistent with previous research,13,14 opioids were the
predominant concomitant acute headache-related treatment
used across all study cohorts. Opioid treatment for acute
headache is highly controversial, as there are a number of
adverse events (AEs) associated with acute and chronic
opioid treatment,21 including euphoria, sedation, sleep dis-
turbance, respiratory depression, cough suppression, pupil-
lary constriction, truncal rigidity, and nausea and vomiting.
Additionally, AEs with opioids may be amplified when use
is daily, which may include significant gastrointestinal dys-
function, dependence, and addiction. Overuse of opioids
may be associated with worsening of migraine, increasing
the risk of chronic migraine.22 High rates of resource uti-
lization (inpatient and ED admissions) have been reported




















TTH 9.6 10.0 8.3 10.3 8.9 5.9 8.7 8.1
Migraine 96.7 96.1 96.7 98.6 98.1 98.2 98.3 98.5
CH 2.7 3.0 4.5 1.8 1.7 2.4 1.8 2.3
CCI: Charlson Comorbidity Index; CDHP: consumer-driven health plan; CH: cluster headache; EPO: exclusive provider organization; FFS: fee-for-
service; GERD: gastroesophageal reflux disease; HDHP: high-deductible health plan; HMO: health maintenance organization; POS: point of service; PPO:
preferred provider organization; SD: standard deviation; TTH: tension-type headache.
aSpecific primary/secondary headaches and comorbidities <5% have not been reported.
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evidence of concomitant opioid medication use.13,23 More-
over, opioid use for migraine resulted in more severe
headache-related disability, symptomology, and comorbid-
ities (primarily psychiatric and cardiovascular) and greater
HCRU.24
Solutions to minimize opioid use among patients diag-
nosed with major headache disorders are needed. Success-
ful management of the disorder depends on patient–
provider collaboration. Detailed records or patient diaries
with information on headache days, severity, medication
Table 3. Treatment patterns among patients diagnosed with major headache disorders.
Characteristics
TTH Migraine CH >1 Headache type
N ¼ 34,147 N ¼ 363,976 N ¼ 4326 N ¼ 16,330
Measured over the follow-up period
Analgesic medication usea
Any analgesic, n (%) 18,346 (53.7) 228,314 (62.7) 2562 (59.2) 11,899 (72.9)
Number of claims, mean (SD) 3.1 (6.1) 4.2 (7.3) 3.8 (6.9) 5.9 (8.9)
Opioids, n (%) 12,237 (35.8) 164,617 (45.2) 1886 (43.6) 8648 (53.0)
NSAIDs, n (%) 10,551 (30.9) 123,776 (34.0) 1318 (30.5) 6683 (40.9)
Sedatives, n (%) 4092 (12.0) 53,026 (14.6) 440 (10.2) 3789 (23.2)
Psychotropic drug usea
Any psychotropic, n (%) 19,343 (56.6) 256,257 (70.4) 2574 (59.5) 13,142 (80.5)
Number of claims, mean (SD) 8.4 (13.5) 11.9 (16.0) 8.5 (13.8) 15.3 (17.6)
Hypnotics, n (%) 2952 (8.6) 41,701 (11.5) 413 (9.5) 2290 (14.0)
Anxiolytics, n (%) 7424 (21.7) 91,883 (25.2) 860 (19.9) 5009 (30.7)
Antipsychotics, n (%) 1123 (3.3) 21,571 (5.9) 173 (4.0) 1237 (7.6)
Mood stabilizers, n (%) 7386 (21.6) 147,584 (40.5) 1451 (33.5) 8310 (50.9)
Stimulants, n (%) 1192 (3.5) 14,661 (4.0) 144 (3.3) 626 (3.8)
Antidepressants, n (%) 13,990 (41.0) 172,499 (47.4) 1431 (33.1) 9560 (58.5)
Use of recognized treatments, n (%)
Prophylactic PDC, mean (SD) 0.2 (0.3) 0.3 (0.4) 0.3 (0.4) 0.4 (0.4)
Beta-blockers 2633 (7.7) 55,516 (15.3) 418 (9.7) 2812 (17.2)
Tricyclic antidepressants 3853 (11.3) 55,312 (15.2) 404 (9.3) 3975 (24.3)
Serotonin/norepinephrine reuptake inhibitor 3534 (10.3) 44,823 (12.3) 308 (7.1) 2355 (14.4)
Anticonvulsants 5367 (15.7) 121,753 (33.5) 1128 (26.1) 6985 (42.8)
Botox 88 (0.3) 3586 (1.0) 18 (0.4) 256 (1.6)
Steroids 5289 (15.5) 62,622 (17.2) 1122 (25.9) 3579 (21.9)
Verapamil 398 (1.2) 13,716 (3.8) 1192 (27.6) 1285 (7.9)
Others 99 (0.3) 1714 (0.5) 113 (2.6) 158 (1.0)
Acute
NSAIDs 7420 (21.7) 89,937 (24.7) 962 (22.2) 4820 (29.5)
Number of claims, mean (SD) 0.5 (1.6) 0.6 (1.8) 0.6 (1.8) 0.8 (2.1)
Opioids 12,487 (36.6) 169,443 (46.6) 1915 (44.3) 8833 (54.1)
Number of claims, mean (SD) 1.7 (4.5) 2.7 (5.9) 2.6 (6.3) 3.6 (7.0)
Weak opioidsb 4887 (14.3) 65,221 (17.9) 651 (15.0) 3811 (23.3)
Strong opioidsc 10,079 (29.5) 142,951 (39.3) 1639 (37.9) 7455 (45.7)
Ergotamines 50 (0.1) 3565 (1.0) 68 (1.6) 309 (1.9)
Triptans 3535 (10.4) 183,243 (50.3) 1720 (39.8) 8013 (49.1)
Oxygen 151 (0.4) 2342 (0.6) 773 (17.9) 545 (3.3)
Lidocaine 720 (2.1) 8700 (2.4) 116 (2.7) 434 (2.7)
Octreotide 2 (0.0) 36 (0.0) 1 (0.0) 4 (0.0)
Antihistamines 2974 (8.7) 68,852 (18.9) 482 (11.1) 3597 (22.0)
Antiemetics 1295 (3.8) 31,632 (8.7) 255 (5.9) 1689 (10.3)
CH: cluster headache; PDC: proportion of days covered; SD: standard deviation; TTH: tension-type headache.
aMedication classes grouped according to Medi-Span Master Drug Database classification using prescription claims information.
bWeak opioids: butorphanol tartrate, codeine sulfate (including combinations with butalbital/aspirin/caffeine, acetaminophen, butalbital/acetaminophen/
caffeine, carisoprodol/aspirin, aspirin/salicylamide/acetaminophen, and caffeine), nalbuphine HCl, pentazocine lactate (including combinations with
naloxone HCl, acetaminophen, and aspirin), propoxyphene HCl/napsylate (withdrawn from market in November 2010, including combinations with
acetaminophen and aspirin/caffeine), and tramadol (including combinations with glucosamine sulfate and acetaminophen).
cStrong opioids: alfentanil HCl, buprenorphine HCl (including combinations with naloxone HCl), fentanyl (including combinations with droperidol,
bupivacaine HCl, and ropivacaine HCl), hydromorphone HCl (including combinations with bupivacaine HCl), hydrocodone bitartrate (including
combinations with acetaminophen, aspirin, and ibuprofen), levorphanol tartrate, meperidine HCl (including combinations with atropine sulfate and
promethazine HCl), methadone HCl, morphine sulfate (including combinations with naltrexone HCl), opium (including combinations with belladonna
alkaloids), oxycodone HCl (including combinations with acetaminophen, aspirin, and ibuprofen), oxymorphone HCl, remifentanil HCl, and sufentanil
citrate (including combinations with bupivacaine HCl and ropivacaine HCl).
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use, response and adverse effects, headache triggers, and so
on, and frequent review of this information by the provider
and patient can help develop better preventive strategies
tailored to the individual patient.25 Oral cycling and high
switching rate may also infer patient dissatisfaction.26
Patients should be switched to non-oral/fast-acting treat-
ments to optimize management of acute migraine episodes
first rather than opioids. Additional real-world data on
opioid use and dosage in the treatment of major headache
disorders and their effectiveness are warranted.
Earlier this year, the FDA approved three targeted pre-
ventive therapies for migraine in calcitonin gene-related
peptide monoclonal antibody drugs, ushering in a new era
of migraine treatment. Studies using more recent data that
evaluate the effect of this new class of therapies on opioid
use in this population are required. As recently as January
2020, The Institute for Clinical and Economic Review
released an evidence report assessing the comparative
clinical effectiveness and economic value of lasmiditan
(Reyvow™, Eli Lilly), rimegepant (Biohaven), and ubro-
gepant (Ubrelvy™, Allergan).27 The report concludes that
triptans will likely remain first-line therapy for patients
with acute migraine, who can tolerate triptans, as the evi-
dence suggests that lasmiditan, rimegepant, and ubroge-
pant all offer either a comparable or inferior net health
benefit to triptans. They appear to be less effective overall
than triptans and are expected to have a comparatively
higher price tag.
Limitations
Claims data are not inherently designed for research and
therefore do not capture clinical severity measures and
patient characteristics that might influence physician pre-
scribing behavior. Additional insight from physician notes
on observed high opioid use and other treatment patterns
were not available. While claims data allow for the
determination of the medications prescribed to patients,
they do not lend insight into how the medications were
used, nor provide data on reasons for discontinuation/non-
persistence. This is a principal limitation, especially when
studying medications taken as needed, rather than in a
prescribed regimen. Information on over-the-counter
medication use was not available. Further, a prescription
filled does not always translate to medication use. Adher-
ence/persistence results obtained using claims data should
be evaluated with the above limitations in mind. Addition-
ally, prescription data lack information on the primary
diagnosis associated with the prescription claim. There-
fore, some of the acute and prophylactic treatments dis-
cussed above could have been prescribed for comorbid
conditions prevalent in the study population, other than
the primary headache disorders. Limitations related to the
accuracy of coding in the claims data may also affect
study results. Prevalence of secondary headache types and
suicidal ideation and attempt, as well as symptoms of
interest (photophobia and phonophobia), were underesti-
mated due to lack of coding. The database only provides
information on medications received in an outpatient set-
ting; administration of headache-related treatments in an
inpatient setting could not be captured. However, such
events, if any, should have been rare. Additionally, the
coding system used to capture diagnoses in claims data
transitioned from the 9th to the 10th Revision on October
1, 2015, which could impact the identification of the study
population across calendar years and the prevalence of
diseases and symptoms. The study analyzed data up to
December 2017, following which there has been signifi-
cant media coverage and awareness regarding opioid
overuse; the use of opioids within this patient population
may have changed since then. Finally, the results are only
generalizable to a population insured through employer-
sponsored plans and may not be applicable to other popu-





















































































Figure 1. Sumatriptan routes of administration by headache type. CH: cluster headache; TTH: tension-type headache.
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Table 4. Treatment patterns among triptan initiators.
Characteristics
All Sumatriptan Zolmitriptan Naratriptan Rizatriptan Almotriptan Eletriptan Frovatriptan
N ¼ 229,946 n¼ 156,245 n ¼ 7524 n ¼ 3922 n ¼ 47,628 n ¼ 929 n ¼ 11,622 n ¼ 2076
Measured over the follow-up
period
Analgesic medication usea
Any analgesic, % 58.4 58.0 58.1 63.2 58.6 59.1 60.5 61.2
Number of claims,
mean (SD)
3.0 (5.7) 3.0 (5.6) 3.5 (6.4) 3.9 (6.5) 3.1 (5.7) 3.1 (5.5) 3.4 (6.0) 3.8 (6.6)
Opioids,% 40.6 40.1 42.0 41.8 41.2 43.7 42.8 42.7
NSAIDs,% 34.1 33.9 32.5 40.5 33.9 33.9 35.3 34.0
Sedatives,% 10.6 10.5 11.2 11.8 10.5 7.3 11.3 12.1
Psychotropic drug usea
Any psychotropic, % 64.8 63.2 68.0 73.9 67.4 68.7 69.5 70.8
Number of claims,
mean (SD)
8.5 (12.2) 8.0 (11.9) 9.9 (13.1) 11.6 (14.1) 9.0 (12.4) 10.8 (14.0) 10.2 (13.2) 10.8 (13.9)
Hypnotics,% 9.5 9.0 11.4 11.9 9.9 12.3 12.3 12.7
Anxiolytics,% 22.7 22.0 24.2 25.9 23.7 25.4 24.8 26.1
Antipsychotics,% 5.3 5.2 6.0 8.3 5.2 6.0 5.4 7.1
Mood stabilizers,% 33.9 32.1 38.3 46.9 36.2 40.2 40.1 39.5
Stimulants,% 4.4 4.2 4.8 4.5 4.6 4.1 5.2 5.0





0.3 (0.3) 0.2 (0.3) 0.3 (0.4) 0.3 (0.4) 0.3 (0.3) 0.3 (0.4) 0.3 (0.4) 0.3 (0.4)
Any prophylactic 56.5 55.1 59.7 67.0 58.1 59.4 60.6 60.6
Beta-blockers 12.1 12.0 13.3 16.7 12.2 13.1 12.5 11.4
Tricyclic
antidepressants




11.2 10.9 12.0 13.1 11.7 11.0 12.0 12.8
Anticonvulsants 28.1 26.6 30.8 37.9 30.1 32.7 33.1 32.6
Botox 0.6 0.5 1.4 1.8 0.7 1.2 1.1 2.2
Steroids 17.9 17.7 18.5 19.8 17.9 16.9 18.7 18.4
Verapamil 3.2 3.0 4.7 4.8 3.1 4.0 3.4 4.3
Others 0.5 0.5 0.6 0.6 0.4 0.6 0.5 0.6
Acute
NSAIDs 25.7 26.0 23.7 30.1 24.8 23.9 25.7 25.1
Opioids 41.7 41.2 42.8 42.6 42.3 44.8 43.5 43.4
Opioids number of
claims, Mean (SD
1.9 (4.7) 1.9 (4.7) 2.2 (5.2) 2.3 (5.4) 1.9 (4.7) 1.8 (4.2) 2.1 (4.9) 2.4 (5.4)
Weak opioidsb 16.1 15.9 16.5 17.0 16.3 16.8 16.7 15.7
Strong opioidsc 34.6 34.2 35.7 35.7 35.1 36.5 36.2 38.0
Ergotamines 0.7 0.7 1.4 2.5 0.7 1.3 1.0 2.0
Oxygen 0.6 0.6 1.0 0.6 0.5 0.4 0.5 0.4
Lidocaine 2.1 2.0 2.2 2.4 2.2 2.3 2.4 3.0
Octreotide 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Antihistamine 17.1 17.0 16.5 18.7 17.3 15.3 17.0 16.4
Antiemetic 7.9 8.1 7.6 10.9 7.2 7.0 6.9 7.7
CH: cluster headache; NSAID: nonsteroidal anti-inflammatory drug; PDC: proportion of days covered; SD: standard deviation; TTH: tension-type
headache.
aMedication classes grouped according to Medi-Span Master Drug Database classification using prescription claims information.
bWeak opioids: butorphanol tartrate, codeine sulfate (including combinations with butalbital/aspirin/caffeine, acetaminophen, butalbital/acetaminophen/
caffeine, carisoprodol/aspirin, aspirin/salicylamide/acetaminophen, and caffeine), nalbuphine HCl, pentazocine lactate (including combinations with
naloxone HCl, acetaminophen, and aspirin), propoxyphene HCl/napsylate (withdrawn from market in November 2010, including combinations with
acetaminophen and aspirin/caffeine), and tramadol (including combinations with glucosamine sulfate and acetaminophen).
cStrong opioids: alfentanil HCl, buprenorphine HCl (including combinations with naloxone HCl), fentanyl (including combinations with droperidol,
bupivacaine HCl, and ropivacaine HCl), hydromorphone HCl (including combinations with bupivacaine HCl), hydrocodone bitartrate (including
combinations with acetaminophen, aspirin, and ibuprofen), levorphanol tartrate, meperidine HCl (including combinations with atropine sulfate and
promethazine HCl), methadone HCl, morphine sulfate (including combinations with naltrexone HCl), opium (including combinations with belladonna
alkaloids), oxycodone HCl (including combinations with acetaminophen, aspirin, and ibuprofen), oxymorphone HCl, remifentanil HCl, and sufentanil
citrate (including combinations with bupivacaine HCl and ropivacaine HCl).
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Conclusion
In conclusion, this study supports existing perspectives on
primary headache disorders as complex, with significant
variability in treatment patterns. Patients diagnosed with
>1 primary headache type have higher comorbidity and
economic burden.
Patients diagnosed with CH have evidence of triptan use
and are more likely to use non-oral triptans, probably due to
the relatively quicker onset and higher severity of a head-
ache episode among CH patients compared with patients
diagnosed with other major headache disorders. However,
60% of CH patients with evidence of sumatriptan used oral
sumatriptan at least once, highlighting the need for therapy
tailored to the headache type and severity.
Predominant concomitant use of any opioids across all
primary headache types (35.8–53.0%)—and specifically
strong opioids—and high rates of switching to opioids are
of concern and may be indicative of poor treatment
optimization.
Further studies are needed to understand the role of
natural disease progression, including the burden of other
comorbidities, while evaluating physician prescribing
behaviors for various headache-related treatments.
In-depth analysis of the use of opioids for headache
treatment is also recommended.
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